BioSpace News Archive

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced that it has commenced an underwritten public offering of shares of its common stock.

Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care

Omeros Corporation announced that it has commenced a registered underwritten public offering of its common stock.

Awards presented during cocktail reception sponsored by Ambra Health at the annual RSNA conference.

The presentation will be webcast. Links to the live and archived webcast will be available on Veeva’s investor relations website at ir.veeva.com

The aggregate net proceeds from the note are approximately $1.94 million, after deducting the initial purchaser’s discount, commissions and estimated offering expenses.

Company gained FDA alignment on the final content of the BLA

Nasdaq Rule 5550(a)(2) requires the Shares to maintain a minimum bid price of US$1.00 per Share, and Nasdaq Rule 5810(c)(3)(A) provides that failure to meet such a requirement exists when the bid price of the Shares is below US$1.00 for a period of 30 consecutive business days.

Piramal Enterprises Limited’s Pharma Solutions business, a leading Contract Development and Manufacturing Organization (CDMO), today announced that the company will be partnering with BerGenBio ASA (OSE:BGBIO) on the development of bemcentinib for the treatment of elderly patients with relapsed Acute Myeloid Leukemia (AML).

Quadrant Biosciences Inc., a developer of novel diagnostic solutions, announced the release of Clarifi ASD™, the first ever epigenetic test for autism spectrum disorder (ASD).